The Technical Analyst
Annexon, Inc. [ANNX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Annexon, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
3.27% $4.74
America/New_York / 26 apr 2024 @ 14:46
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 498.11 mill |
| EPS: | -1.770 |
| P/E: | -2.68 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 105.09 mill |
| Avg Daily Volume: | 1.649 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.68 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.46x |
| Company: PE -2.68 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.56 (-45.98%) $-2.18 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.06 - 5.42 ( +/- 14.32%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-08 | Carson William H. | Buy | 3 200 | Common Stock |
| 2024-02-16 | Love Douglas | Buy | 656 200 | Stock Option (Right to Buy) |
| 2024-02-16 | Dananberg Jamie | Buy | 160 000 | Stock Option (Right to Buy) |
| 2024-02-16 | Dananberg Jamie | Buy | 39 000 | Common Stock |
| 2024-02-16 | Artis Dean Richard | Buy | 160 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 80.78 |
| Last 94 transactions |
| Buy: 9 088 380 | Sell: 879 119 |
Forecast:
16:00 - $4.74
Live Trading Signals (every 1 min)
Forecast
1: 14:55 - $4.75
Forecast 2: 15:45 - $4.75
Forecast 3: 16:00 - $4.74
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.74 (3.27% ) |
| Volume | 0.708 mill |
| Avg. Vol. | 1.649 mill |
| % of Avg. Vol | 42.90 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ANNX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $5.42 | N/A | Active |
|---|
ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Latest Press Releases
2024-04-16 16:05:00 - Press Release
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(c)(4)
Brisbane, calif., april 16, 2024 (globe newswire) -- annexon, inc. (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 employment inducement award plan. the equity awards were approved on april 12, 2024, in accordance with nasdaq listing rule 5635(c)(4).
2024-04-03 08:00:00 - Press Release
Annexon Biosciences To Present At The 23rd Annual Needham Virtual Healthcare Conference
Brisbane, calif., april 03, 2024 (globe newswire) -- annexon, inc. (nasdaq: annx), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that douglas love, president and chief executive officer, will participate in a fireside chat at the 23rd annual needham virtual healthcare conference on wednesday, april 10, 2024 at 11:00 a.m. et.
2024-03-26 16:05:00 - Press Release
Annexon Reports Fourth Quarter And Year-end 2023 Financial Results And Key Anticipated Milestones
Pivotal phase 3 data for anx005 in guillain-barrÉ syndrome (gbs) expected in second quarter 2024 initiation of pivotal phase 3 anx007 archer ii trial in geographic atrophy (ga) expected in mid-2024, a global sham-controlled trial using vision preservation as primary outcome measure clinical proof-of-concept data with anx1502 oral inhibitor of the classical pathway expected in second half of 2024 robust balance sheet with cash, cash equivalents, and short-term investments of approximately $260 million as of december 31, 2023, and anticipated runway into mid-2026 brisbane, calif., march 26, 2024 (globe newswire) -- annexon, inc. (nasdaq: annx), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported fourth quarter and full year 2023 financial results.
2024-03-18 16:05:00 - Press Release
Annexon Reports Inducement Grant To New Employee Under Nasdaq Listing Rule 5635(c)(4)
Brisbane, calif., march 18, 2024 (globe newswire) -- annexon, inc. (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 employment inducement award plan. the equity award was approved on march 15, 2024, in accordance with nasdaq listing rule 5635(c)(4).
2024-02-27 08:00:00 - Press Release
Annexon Biosciences To Present At The Td Cowen 44th Annual Health Care Conference
Brisbane, calif., feb. 27, 2024 (globe newswire) -- annexon, inc. (nasdaq: annx) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that douglas love, president and chief executive officer, will participate in a corporate panel discussion focused on ophthalmology, at the td cowen 44th annual health care conference on tuesday, march 5, 2024 at 12:10 p.m. et in boston, ma.
Latest News
2024-04-17 10:46:43 - Zacks Investment Research
Are Medical Stocks Lagging Annexon (ANNX) This Year?
Here is how Annexon, Inc. (ANNX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
2024-04-10 19:21:22 - Zacks Investment Research
Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Annexon, Inc. (ANNX) closed at $6.17, marking a -0.96% move from the previous day.
2024-04-01 13:00:47 - Zacks Investment Research
What Makes Annexon (ANNX) a New Buy Stock
Annexon (ANNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-04-01 10:56:09 - Zacks Investment Research
Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 101.1% in Annexon (ANNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-03-14 09:40:14 - Zacks Investment Research
Why Annexon (ANNX) Might Surprise This Earnings Season
Annexon (ANNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2024-01-17 12:11:06 - Zacks Investment Research
Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How
Annexon (ANNX) has rallied 156% in the past three months on plans to begin a registrational program for ANX007 in GA after reaching FDA alignment on the study's primary endpoint.
2023-12-27 06:30:00 - GlobeNewsWire
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. PT in San Francisco.
2023-12-23 12:00:00 - Seeking Alpha
Annexon: ANX007 Advances Forward With Stellar Endpoint
Alignment with FDA reached to have phase 3 ARROW study use Best Corrected Visual Acuity ≥ 15-Letter Loss as the primary endpoint; Significance of this could mean competitive advantage. A sham-controlled trial, known as ARCHER II expected to begin in mid-2024, could provide a quicker pathway towards European regulatory approval. The prior phase 2 ARCHER study showed that patients given ANX-007 achieved the endpoint of protection of vision loss measured by BCVA compared to baseline.
2023-09-19 06:30:00 - GlobeNewsWire
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 8:10 a.m. ET in NYC.
2023-09-08 11:18:11 - Zacks Investment Research
Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX)
Annexon, Inc. (ANNX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.